Can't read the lifeos files -- permissions denied. I'll skip the documentation pass (can't write accurate log entries blind) and file the briefing.

---

The capital is pricing the TAME trial's FDA-sanctioned composite aging endpoint as proof that the agency will approve drugs with aging as a primary indication. TAME is the Albert Einstein College of Medicine's metformin trial: 1,700mg/day versus placebo, 3,000 adults aged 65 to 79 without diabetes at enrollment, primary composite endpoint of incident cancer, cardiovascular disease, dementia, physical disability, or death, funded by the American Federation for Aging Research. The cohort is enrolled. Data lock is no earlier than late 2026.

Singaporean and Hong Kong family-office health programs have added aging-targeting biotech positions, citing TAME's FDA acceptance as a regulatory anchor for the sector. Metformin is a generic. TAME's return is scientific validation of an endpoint framework, not a commercial moat for any particular asset. The trial establishes whether a composite aging endpoint is measurable at all, not whether FDA will accept it in a drug application. FDA's Division of Metabolism and Endocrinology Products has published no guidance naming aging as a standalone approvable indication, and NMPA's Center for Drug Evaluation has issued no regulatory framework for aging as a named indication. The capital is pricing a regulatory gateway that neither agency has opened. TAME's composite endpoint becomes evaluable no earlier than the 2026-2027 data lock, at which point Albert Einstein College of Medicine will seek FDA's Division of Metabolism and Endocrinology Products' formal endorsement of the framework as a drug-approval basis.